A
A. Chiappori
Researcher at Katholieke Universiteit Leuven
Publications - 8
Citations - 1914
A. Chiappori is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Durvalumab & Chemoradiotherapy. The author has an hindex of 3, co-authored 8 publications receiving 1290 citations.
Papers
More filters
Journal ArticleDOI
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Cheol Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +32 more
TL;DR: Durvalumab therapy resulted in significantly longer overall survival than placebo, and no new safety signals were identified.
Journal ArticleDOI
A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
Bradford A. Perez,Sang-We Kim,Thomas J. Dilling,K. Latifi,Trevor Rose,A. Lannon,G. Macmillan,G.D. Grass,A. Chiappori,Eric B. Haura,Ben C. Creelan,Jhanelle E. Gray,Tawee Tanvetyanon,Michael Shafique,Andreas Saltos,Stephen A. Rosenberg,Michael J. Schell,Scott J. Antonia +17 more
Journal ArticleDOI
P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
A. Chiappori,Charles Williams,Benjamin C. Creelan,Tawee Tanvetyanon,Jhanelle E. Gray,E. Haura,Dung-Tsa Chen,Ram Thapa,Amer A. Beg,Theresa A. Boyle,M. Sangani,Erick Morris,A. Tao,Felipe K. Hurtado,Luigi Manenti,J. Castro,S.J. Antonia +16 more
Journal ArticleDOI
Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
S.J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,K.H. Lee,M. de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Yun-Hyeon Kim,Chris Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,J. De Castro Carpeno,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,C. Wadsworth,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +31 more
Journal ArticleDOI
PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC
Rina Hui,Mustafa Ozguroglu,Davey B. Daniel,D.V. Baz,Shuji Murakami,Takashi Yokoi,A. Chiappori,K.H. Lee,M. de Wit,B. Chul Cho,Jhanelle E. Gray,Anna Rydén,L. Viviers,L. Poole,Phillip A. Dennis,Scott J. Antonia +15 more